May 20, 2021
Altavant Sciences Reports Rodatristat Ethyl PK/PD Analysis at ATS Supporting Doses Selected for Phase 2b ELEVATE 2 Study
Altavant Sciences presented findings at the recent ATS meeting from a dose-response model, which simulated daily administration of rodatristat ethyl to identify optimal doses for the Phase 2b ELEVATE 2 study.
May 10, 2021
Altavant Sciences Provides Update on Clinical Plan for PAH Candidate, Rodatristat Ethyl, at Upcoming American Thoracic Society Annual Meeting
Altavant Sciences will be providing an update on the clinical development of rodatristat ethyl, the company's lead candidate for the treatment of pulmonary arterial hypertension (PAH), at the annual meeting of the American Thoracic Society.
May 6, 2021
Altavant Sciences Advances Rodatristat Ethyl into Phase 2b Clinical Trial for Pulmonary Arterial Hypertension
April 26, 2021
Altavant Sciences Finds Nebulized ALTA-2530 Retains Potency and Reaches Target Lung Tissues, Supporting Continued Investigation for Treatment of BOS
Altavant Sciences presented results of in vitro and in vivo studies for nebulized ALTA-2530, a novel inhaled formulation of recombinant human IL-1Ra currently in nonclinical development for the treatment of BOS
February 18, 2021
Altavant Sciences Initiates Chemical Lung Injury Program in Collaboration with the BARDA and NIAID
Altavant Sciences has partnered with the US Department of Health and Human Services (HHS) BARDA and NIAID to execute an initial in vivo proof-of-concept pilot study of ALTA-2530, a novel inhaled formulation of a recombinant IL-1Ra for the treatment of acute and chronic lung injuries
August 5, 2020
Altavant Sciences Presentation at ATS 2020 Confirms Minimal Brain Exposure of Peripherally Acting Serotonin Modulator, Rodatristat Ethyl, in Clinical Development for PAH
Altavant Sciences presented results from in vivo nonclinical studies of rodatristat ethyl, which demonstrated enhanced distribution in lung tissue consistent with levels associated with disease modification in preclinical models
March 2, 2020
Altavant Sciences Appoints Respiratory Disease Medical Expert as Chief Medical Officer
Altavant Sciences appointed Howard M. Lazarus, M.D., to the newly created position of Chief Medical Officer. Dr. Lazarus brings more than 20 years of experience in drug development for pulmonary vascular and interstitial diseases and as a practicing pulmonologist.
January 8, 2020
Altavant Sciences Acquires Onspira Therapeutics, Adding a Potentially Life-Saving Treatment for Post-Lung Transplant Patients to the Altavant Pipeline
October 22, 2019
Altavant Sciences Presents Data at CHEST 2019 Supporting Once-Daily Dosing of Rodatristat Ethyl for the Treatment of Pulmonary Arterial Hypertension
Altavant Sciences announced mechanistic preclinical pharmacodynamic and Phase 1 data supporting once-daily dosing of rodatristat ethyl for the treatment of PAH. These data were presented as a poster delivered as a short oral presentation at CHEST2019
October 18, 2019
Altavant Sciences to Present Data Supporting Once-Daily Dosing of Rodatristat Ethyl at CHEST 2019
Altavant Sciences announced that its scientific team will be presenting preclinical safety, PK and biomarker PD data at the annual CHEST 2019 meeting being held October 19 - 23 in New Orleans, Louisiana.
October 1, 2019
Altavant Sciences Presents Data at ERS International Congress 2019 Demonstrating Strong Safety and Tolerability Profile of Rodatristat Ethyl
Altavant Sciences announced new clinical data from two Phase 1 trials of rodatristat ethyl, demonstrating favorable safety and tolerability in healthy volunteers, and mechanistic biomarker data consistent with efficacy in nonclinical models of PAH
September 24, 2019
Altavant Sciences to Present New Rodatristat Ethyl Clinical Biomarker and Safety Findings at the ERS International Congress 2019
Altavant Sciences announced that its scientific team will present clinical safety, PK and biomarker data from two Phase 1 clinical studies of rodatristat ethyl at the 29th ERS being held September 28 - October 2 in Madrid, Spain.
September 5, 2019
Sumitomo Dainippon Pharma and Roivant Sciences Enter into a Memorandum of Understanding to Create Broad Strategic Alliance to Deliver Promising New Medicines to Patients
Sumitomo Dainippon Pharma and Roivant Sciences announced the creation of a novel and broad Alliance to include the transfer to Sumitomo Dainippon Pharma of Roivant's ownership interests in 5 of their biopharmaceutical companies, with options to acquire up to 6 additional Vants, and access to Roivant's proprietary technology platforms, DrugOme and Digital Innovation
September 5, 2019
Altavant Sciences Presents Patient-Centric Approach to Drug Development at PHA’s Annual PHPN Symposium
Altavant Sciences today announced a poster presentation describing the company's unique, patient-centric drug development process at the Pulmonary Hypertension Association's Annual PHPN Symposium taking place September 5-7, 2019 in Washington, D.C.
August 5, 2019
Altavant Sciences Initiates Phase 2a Study of Rodatristat Ethyl in Pulmonary Arterial Hypertension
Altavant Sciences dosed the first patient in the ELEVATE 1 proof-of-concept Phase 2a study of rodatristat ethyl in patients with PAH. The study is designed to provide valuable safety, target engagement and biomarker information
May 9, 2019
Altavant Sciences to Provide Clinical Update at 2019 Respiratory Innovation Summit
Altavant Sciences today announced that it has been invited to present at the 2019 Respiratory Innovation Summit May 17 in Dallas, TX. Lyn Baranowski, will present an overview of the company and its lead tryptophan hydroxylase (TPH) inhibitor
January 31, 2019
Altavant Sciences to Present Data Supporting Planned Phase 2 Clinical Program for Rodatristat Ethyl in Patients with Pulmonary Arterial Hypertension at PVRI World Congress
Altavant Sciences will present its latest nonclinical and clinical data at the PVRI 13th Annual World Congress on Pulmonary Vascular Disease, taking place in Barcelona from January 30 to February 3, 2019. These results provide additional evidence that treatment with rodatristat ethyl facilitates vascular remodeling and ameliorates PAH in animal models.
January 2, 2019
Altavant Sciences Appoints Lyn Baranowski Chief Operating Officer
Altavant Sciences announced the appointment of Lyn Baranowski as Chief Operating Officer. In this new position, she will be involved in the general management of the company, leading cross-functional teams to establish and execute on a business and financing strategy that will deliver on the company's short- and long-term business objectives.